J Quentin Clemens1, Jason J Kutch2, Emeran A Mayer3, Bruce D Naliboff3, Larissa V Rodriguez4, David J Klumpp5, Anthony J Schaeffer5, Karl J Kreder6, Daniel J Clauw7, Steven E Harte7, Andrew D Schrepf7, David A Williams7, Gerald L Andriole8, H Henry Lai8, Dedra Buchwald9, M Scott Lucia10, Adrie van Bokhoven10, Sean Mackey11, Robert M Moldwin12, Michel A Pontari13, Alisa J Stephens-Shields14, Chris Mullins15, J Richard Landis14. 1. Department of Urology, Michigan Medicine, Ann Arbor, Michigan. 2. Division of Biokinesiology and Physical Therapy, University of Southern California, Los Angeles, California. 3. Department of Medicine, David Geffen School of Medicine at The University of California, Los Angeles, California. 4. Departments of Urology & Obstetrics and Gynecology, University of Southern California, Los Angeles, California. 5. Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois. 6. Department of Urology, University of Iowa Hospitals and Clinics, Iowa City, Iowa. 7. Department of Anesthesiology, Chronic Pain and Fatigue Research Center, University of Michigan, Ann Arbor, Michigan. 8. Department of Surgery, Division of Urologic Surgery, Washington University School of Medicine, St Louis, Missouri. 9. Department of Epidemiology and Medicine, Washington State University Institute for Research and Education to Advance Community Health, Seattle, Washington. 10. Department of Pathology, University of Colorado Denver, Aurora, Colorado. 11. Department of Anesthesiology, Perioperative, and Pain Medicine, Division of Pain Medicines, Stanford University School of Medicine, Stanford, California. 12. Department of Urology, Hofstra University School of Medicine, The Arthur Smith Institute for Urology, New Hyde Park, New York. 13. Department of Urology, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania. 14. Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. 15. Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.
Abstract
AIMS: The Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network initiated a second observational cohort study-the Symptom Patterns Study (SPS)-to further investigate the underlying pathophysiology of Urologic Chronic Pelvic Pain Syndrome (UCPPS) and to discover factors associated with longitudinal symptom changes and responses to treatments. METHODS: This multisite cohort study of males and females with UCPPS features a run-in period of four weekly web-based symptom assessments before a baseline visit, followed by quarterly assessments up to 36 months. Controls were also recruited and assessed at baseline and 6 months. Extensive clinical data assessing urological symptoms, nonurological pain, chronic overlapping pain syndromes, and psychosocial factors were collected. Diverse biospecimens for biomarker and microbiome studies, quantitative sensory testing (QST) data under multiple stimuli, and structural and functional neuroimaging scans were obtained under a standardized protocol. RESULTS: Recruitment was initiated (July 2015) and completed (February 2019) at six discovery sites. A total of 620 males and females with UCPPS and 73 Controls were enrolled, including 83 UCPPS participants who re-enrolled from the first MAPP Network cohort study (2009-2012). Baseline neuroimaging scans, QST measures, and biospecimens were obtained on 578 UCPPS participants. The longitudinal follow-up of the cohort is ongoing. CONCLUSIONS: This comprehensive characterization of a large UCPPS cohort with extended follow-up greatly expands upon earlier MAPP Network studies and provides unprecedented opportunities to increase our understanding of UCPPS pathophysiology, factors associated with symptom change, clinically relevant patient phenotypes, and novel targets for future interventions.
AIMS: The Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network initiated a second observational cohort study-the Symptom Patterns Study (SPS)-to further investigate the underlying pathophysiology of Urologic Chronic Pelvic Pain Syndrome (UCPPS) and to discover factors associated with longitudinal symptom changes and responses to treatments. METHODS: This multisite cohort study of males and females with UCPPS features a run-in period of four weekly web-based symptom assessments before a baseline visit, followed by quarterly assessments up to 36 months. Controls were also recruited and assessed at baseline and 6 months. Extensive clinical data assessing urological symptoms, nonurological pain, chronic overlapping pain syndromes, and psychosocial factors were collected. Diverse biospecimens for biomarker and microbiome studies, quantitative sensory testing (QST) data under multiple stimuli, and structural and functional neuroimaging scans were obtained under a standardized protocol. RESULTS: Recruitment was initiated (July 2015) and completed (February 2019) at six discovery sites. A total of 620 males and females with UCPPS and 73 Controls were enrolled, including 83 UCPPS participants who re-enrolled from the first MAPP Network cohort study (2009-2012). Baseline neuroimaging scans, QST measures, and biospecimens were obtained on 578 UCPPS participants. The longitudinal follow-up of the cohort is ongoing. CONCLUSIONS: This comprehensive characterization of a large UCPPS cohort with extended follow-up greatly expands upon earlier MAPP Network studies and provides unprecedented opportunities to increase our understanding of UCPPS pathophysiology, factors associated with symptom change, clinically relevant patient phenotypes, and novel targets for future interventions.
Authors: John N Krieger; Alisa J Stephens; J Richard Landis; J Quentin Clemens; Karl Kreder; H Henry Lai; Niloofar Afari; Larissa Rodríguez; Anthony Schaeffer; Sean Mackey; Gerald L Andriole; David A Williams Journal: J Urol Date: 2014-10-22 Impact factor: 7.450
Authors: R Rolke; R Baron; C Maier; T R Tölle; - D R Treede; A Beyer; A Binder; N Birbaumer; F Birklein; I C Bötefür; S Braune; H Flor; V Huge; R Klug; G B Landwehrmeyer; W Magerl; C Maihöfner; C Rolko; C Schaub; A Scherens; T Sprenger; M Valet; B Wasserka Journal: Pain Date: 2006-05-11 Impact factor: 6.961
Authors: Siobhan Sutcliffe; Robert Gallop; Hing Hung Henry Lai; Gerald L Andriole; Catherine S Bradley; Gisela Chelimsky; Thomas Chelimsky; James Quentin Clemens; Graham A Colditz; Bradley Erickson; James W Griffith; Jayoung Kim; John N Krieger; Jennifer Labus; Bruce D Naliboff; Larissa V Rodriguez; Suzette E Sutherland; Bayley J Taple; John Richard Landis Journal: BJU Int Date: 2019-05-29 Impact factor: 5.588
Authors: J Quentin Clemens; Talar W Markossian; Richard T Meenan; Maureen C O'Keeffe Rosetti; Elizabeth A Calhoun Journal: J Urol Date: 2007-08-16 Impact factor: 7.450
Authors: Cynthia J Schoen; Jacob N Ablin; Eric Ichesco; Rupal J Bhavsar; Laura Kochlefl; Richard E Harris; Daniel J Clauw; Richard H Gracely; Steven E Harte Journal: J Pain Res Date: 2016-09-26 Impact factor: 3.133
Authors: Steven E Harte; Andrew Schrepf; Robert Gallop; Grant H Kruger; Hing Hung Henry Lai; Siobhan Sutcliffe; Megan Halvorson; Eric Ichesco; Bruce D Naliboff; Niloofar Afari; Richard E Harris; John T Farrar; Frank Tu; John Richard Landis; Daniel J Clauw Journal: Pain Date: 2019-06 Impact factor: 7.926
Authors: H Henry Lai; Craig Newcomb; Steve Harte; Dina Appleby; A Lenore Ackerman; Jennifer T Anger; J Curtis Nickel; Priyanka Gupta; Larissa V Rodriguez; J Richard Landis; J Quentin Clemens Journal: Neurourol Urodyn Date: 2021-02-19 Impact factor: 2.696
Authors: Ishtiaq Mawla; Andrew Schrepf; Eric Ichesco; Steven E Harte; David J Klumpp; James W Griffith; Eric Strachan; Claire C Yang; Henry Lai; Gerald Andriole; Vincent A Magnotta; Karl Kreder; Daniel J Clauw; Richard E Harris; J Quentin Clemens; J Richard Landis; Chris Mullins; Larissa V Rodriguez; Emeran A Mayer; Jason J Kutch Journal: Sci Rep Date: 2020-11-16 Impact factor: 4.379